📈 Stocks · US

Eli Lilly and Stock LLY · Forecast & Analysis

Stocks US ISIN US5324571083
News situation · News, 30 days · no price data
▲ Bullish medium Data coverage good
Price no dataTrend no price dataNews ▲ 20 reports, latest 19.11.

Heads-up: USD Michigan Consumer Sentiment is due in 21 h (high impact). The outlook can shift noticeably around it.

Eli Lilly is bullish on the back of its obesity pipeline: strong Phase 3 data for the oral GLP-1 Foundayo in sleep apnea and fresh ObesityWeek results expand future revenue options. The view rests on news alone; no LLY price history is available here.

News situation · 20 items / 30 D
▲ Bullish medium Data coverage good
4.0 Impact / 10
By source type
Release 15 News 3 Filing 1 Earnings 1

17 of 20 straight from the issuer or regulator

AI-generated · as of November 19, 2026
News, 30 days
Bullish
Outlook

Outlook for Eli Lilly and Company

Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.

News picture · news of the last 30 days only
▲ Bullish medium
Data coverage good

No price statement: there is no price data for this asset. Based on 20 news items.

What drives it
  • Foundayo, the oral GLP-1, met its Phase 3 endpoint in sleep apnea; an FDA submission is planned by year-end.
  • ObesityWeek data for retatrutide and the oral EloraTZP showed deep weight loss and large sleep apnea benefit.
  • A Hims & Hers distribution deal opens a direct-to-consumer channel for Zepbound and Foundayo.
What argues against it
  • Side-effect discontinuations ran well above placebo in a subgroup of the sleep apnea trial.
  • The planned FDA submission is not yet filed, and approval timing remains uncertain.
  • The investigational medicines behind the new data cannot yet be sold, so revenue stays distant.
  • Heavy US data in the coming days, from GDP to PCE inflation, may sway the stock through the macro backdrop.
What would change the picture
  • A year-end FDA filing for the oral GLP-1 in sleep apnea, or a delay in it, would reshape the outlook.
  • Phase 3 results for retatrutide, still investigational, landing clearly better or worse than expected.
Coming up
  • US: Michigan Consumer Sentiment · expected 51.0, previous 51.0
  • US: CB Consumer Confidence Index · expected 91.5, previous 91.7
  • US: Jobless claims, PCE price index, GDP · expected 3.1%, previous 3.1%
All dates ↓ All times UTC.

Economic data for LLY

Full calendar

Recently released

  • TodayUSDInitial Jobless Claims●●●4 h ago
  • TodayUSDPhiladelphia Fed Manufacturing Index●●●Forecast 32.2Previous 20.94 h ago
  • November 18, 2026USDEIA Crude Oil Stocks Change●●●Actual 3.380MForecast -0.309MPrevious 4.657M26 h ago
  • November 17, 2026USDCore Retail Sales m/m●●●Actual 0.6%Forecast 0.7%Previous 1.1%worse than expected for USD2 days ago
  • November 17, 2026USDRetail Sales m/m●●●Actual 0.2%Forecast 0.3%Previous 0.8%worse than expected for USD2 days ago

Coming up

  • TomorrowUSDMichigan Consumer Sentiment●●●Forecast 51.0Previous 51.0in 21h
  • November 24, 2026USDCB Consumer Confidence Index●●●Forecast 91.5Previous 91.7in 4 days
  • November 25, 2026USDInitial Jobless Claims●●●in 5 days
  • November 25, 2026USDCore PCE Price Index y/y●●●Forecast 3.1%Previous 3.1%in 5 days
  • November 25, 2026USDCore PCE Price Index m/m●●●Forecast 0.3%Previous 0.3%in 5 days
  • November 25, 2026USDGDP Sales q/q●●●Forecast 1.7%Previous 1.7%in 5 days
  • November 25, 2026USDGDP q/q●●●Forecast 3.4%Previous 3.4%in 5 days
  • November 25, 2026USDDurable Goods Orders m/m●●●Forecast -0.7%Previous 1.8%in 5 days

All times UTC. Assessed against the consensus forecast, otherwise against the previous value.

Signal history

Both worlds over time

Technical and news signals of the last 30 days on one timeline.

Bullish ▲Bearish ▼24.10. · News signal · Impact 6/1025.10. · News signal · Impact 6/1026.10. · News signal · Impact 2/1027.10. · News signal · Impact 3/1028.10. · News signal · Impact 8/1028.10. · News signal · Impact 3/1029.10. · News signal · Impact 8/1029.10. · News signal · Impact 5/1030.10. · News signal · Impact 5/1002.11. · News signal · Impact 4/1004.11. · News signal · Impact 2/1005.11. · News signal · Impact 4/1005.11. · News signal · Impact 2/1009.11. · News signal · Impact 5/1011.11. · News signal · Impact 4/1012.11. · News signal · Impact 2/1014.11. · News signal · Impact 2/1014.11. · News signal · Impact 4/1016.11. · News signal · Impact 2/1019.11. · News signal · Impact 2/10
30 days ago today
Technical signal News signal Size = strength
News, 30 days

What is being reported about LLY

Release Neutral Impact 2/10
General Medicine Adds GLP-1 Weight Management Care to Eli Lilly's LillyDirect
General Medicine, a private healthcare store, announced its GLP-1 weight management care is now offered as an independent care option on LillyDirect, …
November 19, 2026
Release Neutral Impact 2/10
Eli Lilly to Acquire Calytrix Bio in Deal Valued at Up to $1.5 Billion
Lilly agreed to acquire Calytrix Bio, with shareholders receiving up to $1.5 billion in cash including upfront and milestone payments. The deal broade…
November 16, 2026
Release Bullish Impact 4/10
Eli Lilly Unveils New Clinical Data for Obesity Pipeline at ObesityWeek 2026
At ObesityWeek 2026 (November 14-17) Lilly presents quantified positive data: EloraTZP Phase 2 weight loss up to 23.3% and A1C reduction up to 2.9% at…
November 14, 2026
Release Bullish Impact 2/10
Innovent Biologics Adds 7 Drugs to China's 2026 National Reimbursement List
Eli Lilly licensed mazdutide (OXM3) to Innovent for China and also partners on sintilimab and licenses Jaypirca for Chinese commercialization. NRDL in…
November 14, 2026
Release Neutral Impact 2/10
Eli Lilly Breaks Ground on $3.5 Billion Pennsylvania Manufacturing Site
Lilly broke ground on a $3.5 billion Pennsylvania plant on Nov. 12, 2026 for injectable obesity medicines including retatrutide, within its previously…
November 12, 2026
News Bullish Impact 4/10
Nasdaq Rallies 4% This Week as Markets Navigate Chip Sector Volatility
Lilly is expanding distribution of Zepbound and Foundayo through the Hims & Hers platform with self-pay pricing from $149 to $299 per month, opening a…
November 11, 2026

Frequently asked questions about Eli Lilly and Company

What is the strongest recent news for Eli Lilly and LLY?

The Phase 3 ATTAIN-OSA readout: the oral GLP-1 Foundayo cut sleep apnea severity by up to 43.8% and body weight by roughly 11.5% at 52 weeks, and Lilly plans to file with the FDA for this new use by the end of 2026. That opens a large market beyond obesity for an already approved pill.

Why didn't the strong ObesityWeek data move LLY much?

Conference presentations are largely anticipated: the EloraTZP and retatrutide results were expected strengths of a known pipeline, and neither drug can legally be sold yet. Positive but familiar data tend to support the story rather than trigger a sharp move.

What would change the bullish view on Eli Lilly?

Watch the planned FDA submission for the oral GLP-1 in sleep apnea by year-end: a filing supports the story, a delay weakens it. Retatrutide's Phase 3 progress matters too, since manufacturing capacity is already being built for it. Any safety setback would also weigh on the picture.

Asset Snapshot

📝 Overview Generated automatically

LLY has been the subject of 73 signals across 73 articles in the last 365 days. Sentiment skews Bullish (45%).

Breakdown: 33 bullish, 7 bearish, 33 neutral.

Most-cited catalysts: Supreme Court denies appeal on $194 million Medicaid penalty (1×), Immediate earnings charge in upcoming quarter (1×), Validation of oral GLP-1 category by EMA (1×). Most-cited risk factors: Lilly's strong cash position may mitigate market reaction (1×), Ruling was expected and priced in (1×), Novo's oral Wegovy may establish strong brand loyalty before Lilly's launch (1×).

Keep exploring

Related assets

Same category or comparable signal picture — each card opens the full cockpit.